Although the US Supreme Court recently upheld the constitutionality of the Patient Protection and Affordable Care Act (ACA), the debate still rages on health care reform. Efforts to repeal the ACA are ongoing and there is a great deal of uncertainty as to what impact the new law will actually have on the economy, consumers, providers, and businesses. Whatever the outcome of current discussions, preventive care will remain at the forefront of any health care reform effort, and companies with screening and diagnostic technologies could very well benefit from this changing dynamic in the health care system.
One clinical area that could see a boost from expanded coverage under health care reform is colorectal cancer (CRC) screening. (See Also see "Capsule Endoscopy: Poised For Growth" -...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?